A better ‘map’ of the lights you see when you close your eyes can improve ‘bionic eye’ outcomes
Posted: 17 October 2023 Researchers at Monash University have identified a new way of mapping ‘phosphenes’ – the visual perception of the bright flashes we see when no light is entering the eye – to improve the outcome…
New $15m frontier technology centre to develop next-generation cancer drugs
Posted: 17 October 2023 Australia has a new frontier technology centre that is set to revolutionise drug development for metastatic prostate cancer and childhood neuroblastoma. The Australian Centre for Targeted Therapeutics (ACTT) has been awarded $15 million from…
A well-established drug can improve hand osteoarthritis symptoms: study
Posted: 17 October 2023 Relief could be on the way for people with painful hand osteoarthritis after a Monash University and Alfred Health-led study found an affordable existing drug can help. Until now there has been no effective…
Australian-first trial to transform lives of children with a severe immune deficiency disorder
Posted: 17 October 2023 A cure for a severe immune deficiency disorder in children that makes them extremely vulnerable to infections will be offered in Australia for the first time under a cutting-edge gene therapy trial. Murdoch Children’s…
Melbourne invention brings new hope for rheumatoid arthritis
Posted: 17 October 2023 A new nerve treatment invented by Melbourne researchers at the Bionics Institute is bringing hope to people with rheumatoid arthritis. The tiny piece of ground-breaking technology – the size of a thumbnail – could…
Global non-profit CARB-X awards more than AUD$2.6 million to University of Melbourne’s Doherty Institute to fight antibiotic resistance
Posted: 17 October 2023 University of Melbourne researchers from the Peter Doherty Institute for Infection and Immunity (Doherty Institute) are developing a world-first treatment for antibiotic-resistant community-acquired bacterial pneumonia (CABP). The AUD$2.68M (US$1.75M) award by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator…
Cartherics appoints new Chief Scientific Officer
Posted: 17 October 2023 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately.…
PROOF-OF-CONCEPT CLINICAL TRIAL SUCCESSFULLY COMPLETED WITH LAT8881
Posted: 17 October 2023 Lateral Pharma has successfully completed its LAT8881 Phase 1b clinical trial in patients with chronic lumbar radicular pain (a condition commonly referred to as “sciatica”).1,2 The results from this study have demonstrated clinical “proof-of-concept”…
When cells go boom: study reveals inflammation-causing gene carried by millions
Posted: 12 October 2023 Researchers have found that a genetic change that increases the risk of inflammation, through a process described as ‘explosive’ cell death, is carried by up to 3% of the global population. The WEHI-led study…
Monash University co-leads report into precision medicine in diabetes
Posted: 12 October 2023 A new international consensus report on precision medicine in diabetes prevention and care has been published in Nature Medicine. The report, with Dr Siew Lim, from Monash University’s Eastern Health Clinical School, as the…
Seizure Forecasting App To Empower People With Epilepsy
Posted: 12 October 2023 In 2019 there were approximately 150,000 patients diagnosed with epilepsy resulting in $12.3 billion of direct and indirect costs1,2. It is now estimated that up to 200,000 Australians face the daily prospect of debilitating…
Tails From Southern Africa
Posted: 11 October 2023 Elane Zelcer – My Photographs & Stories from Southern Africa Profits from sales of the book, less printing costs, together with sales from other items, will be donated to the Murdoch Children’s Research Institute (MCRI), Australia’s…
